PURPOSE: Hospitalizations are a common occurrence during chemotherapy for advanced cancer. Validated risk stratification tools could facilitate proactive approaches for reducing hospitalizations by identifying at-risk patients. PATIENTS AND METHODS: We assembled two retrospective cohorts of patients receiving chemotherapy for advanced nonhematologic cancer; cohorts were drawn from three integrated health plans of the Cancer Research Network. We used these cohorts to develop and validate logistic regression models estimating 30-day hospitalization risk after chemotherapy initiation. The development cohort included patients in two health plans from 2005 to 2013. The validation cohort included patients in a third health plan from 2007 to 2016. Candidate predictor variables were derived from clinical data in institutional data warehouses. Models were validated based on the C-statistic, positive predictive value, and negative predictive value. Positive predictive value and negative predictive value were calculated in reference to a prespecified risk threshold (hospitalization risk ≥ 18.0%). RESULTS: There were 3,606 patients in the development cohort (median age, 63 years) and 634 evaluable patients in the validation cohort (median age, 64 years). Lung cancer was the most common diagnosis in both cohorts (26% and 31%, respectively). The selected risk stratification model included two variables: albumin and sodium. The model C-statistic in the validation cohort was 0.69 (95% CI, 0.62 to 0.75); 39% of patients were classified as high risk according to the prespecified threshold; 30-day hospitalization risk was 24.2% (95% CI, 19.9% to 32.0%) in the high-risk group and 8.7% (95% CI, 6.1% to 12.0%) in the low-risk group. CONCLUSION: A model based on data elements routinely collected during cancer treatment can reliably identify patients at high risk for hospitalization after chemotherapy initiation. Additional research is necessary to determine whether this model can be deployed to prevent chemotherapy-related hospitalizations.
PURPOSE: Hospitalizations are a common occurrence during chemotherapy for advanced cancer. Validated risk stratification tools could facilitate proactive approaches for reducing hospitalizations by identifying at-risk patients. PATIENTS AND METHODS: We assembled two retrospective cohorts of patients receiving chemotherapy for advanced nonhematologic cancer; cohorts were drawn from three integrated health plans of the Cancer Research Network. We used these cohorts to develop and validate logistic regression models estimating 30-day hospitalization risk after chemotherapy initiation. The development cohort included patients in two health plans from 2005 to 2013. The validation cohort included patients in a third health plan from 2007 to 2016. Candidate predictor variables were derived from clinical data in institutional data warehouses. Models were validated based on the C-statistic, positive predictive value, and negative predictive value. Positive predictive value and negative predictive value were calculated in reference to a prespecified risk threshold (hospitalization risk ≥ 18.0%). RESULTS: There were 3,606 patients in the development cohort (median age, 63 years) and 634 evaluable patients in the validation cohort (median age, 64 years). Lung cancer was the most common diagnosis in both cohorts (26% and 31%, respectively). The selected risk stratification model included two variables: albumin and sodium. The model C-statistic in the validation cohort was 0.69 (95% CI, 0.62 to 0.75); 39% of patients were classified as high risk according to the prespecified threshold; 30-day hospitalization risk was 24.2% (95% CI, 19.9% to 32.0%) in the high-risk group and 8.7% (95% CI, 6.1% to 12.0%) in the low-risk group. CONCLUSION: A model based on data elements routinely collected during cancer treatment can reliably identify patients at high risk for hospitalization after chemotherapy initiation. Additional research is necessary to determine whether this model can be deployed to prevent chemotherapy-related hospitalizations.
Authors: Jessica Chubak; Rebecca Ziebell; Robert T Greenlee; Stacey Honda; Mark C Hornbrook; Mara Epstein; Larissa Nekhlyudov; Pamala A Pawloski; Debra P Ritzwoller; Nirupa R Ghai; Heather Spencer Feigelson; Heather A Clancy; V Paul Doria-Rose; Lawrence H Kushi Journal: Cancer Causes Control Date: 2016-09-17 Impact factor: 2.506
Authors: Gabriel A Brooks; Ankit J Kansagra; Sowmya R Rao; James I Weitzman; Erica A Linden; Joseph O Jacobson Journal: JAMA Oncol Date: 2015-07 Impact factor: 31.777
Authors: Erin J Aiello Bowles; Leah Tuzzio; Debra P Ritzwoller; Andrew E Williams; Tyler Ross; Edward H Wagner; Christine Neslund-Dudas; Andrea Altschuler; Virginia Quinn; Mark Hornbrook; Larissa Nekhlyudov Journal: Med Care Date: 2009-10 Impact factor: 2.983
Authors: Robin L Whitney; Janice F Bell; Daniel J Tancredi; Patrick S Romano; Richard J Bold; Jill G Joseph Journal: J Clin Oncol Date: 2017-08-29 Impact factor: 50.717
Authors: Gabriel A Brooks; Andrea M Austin; Hajime Uno; Konstantin H Dragnev; Anna N A Tosteson; Deborah Schrag Journal: JAMA Netw Open Date: 2018-10-05
Authors: Bobby Daly; Dmitriy Gorenshteyn; Kevin J Nicholas; Alice Zervoudakis; Stefania Sokolowski; Claire E Perry; Lior Gazit; Abigail Baldwin Medsker; Rori Salvaggio; Lynn Adams; Han Xiao; Yeneat O Chiu; Lauren L Katzen; Margarita Rozenshteyn; Diane L Reidy-Lagunes; Brett A Simon; Wendy Perchick; Isaac Wagner Journal: JCO Clin Cancer Inform Date: 2020-03
Authors: Arthur S Hong; Danh Q Nguyen; Simon Craddock Lee; D Mark Courtney; John W Sweetenham; Navid Sadeghi; John V Cox; Hannah Fullington; Ethan A Halm Journal: JCO Oncol Pract Date: 2021-05-26